We thank Borja Sánchez (Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis: a role for bifidobacteria and lactobacilli? Nat. Rev 3, 4 . The primary BAs sequestered in the cyto plasm of these bacteria might escape from the portal circulation and the action of other micro organisms to produce secondary BAs. Thus, a BA depletion strategy using pro biotics could be a useful means of reducing colonic DCA levels, leading to decreased inflammation and gastrointestinal cancer risk. This concept is certainly an interesting topic for discussion.
However, we believe that it is premature to have included results from an in vitro study 5 in our Review. First, BAs are reabsorbed primarily in the small intestine (terminal ileum), whereas intestinal BA depletion by bacteria is likely to occur in the large intestine where bacteria such as bifido bacteria and lactobacilli are present in sufficient amounts to demonstrate the effect of lowering intes tinal BA concentrations. Probiotics such as Lactobacillus and Bifidobacterium spp. are primarily located in the large intestine, which contains the highest bacterial density, about 10 11 -10 12 bacteria per gram of intesti nal content 6, 7 . In other words, BA binding by pro biotics that occurs predomin antly in the large intestine will probably not affect the apical sodiumdependent BA transporter mediated BA reabsorption that takes place in the upper intestine. Thus, the proposed BA removal strategy via probiotics might not be practically achievable in vivo. Secondly, the ability of a given probiotic to bind and release BAs has not been well studied in vivo. Unlike the action of a BA sequestrant resin such as cholestyramine, the probiotic strains must grow to achieve a suffi cient amount in the intestine for the binding to become sub stantial and have notable effects. Although BAs are absorbed by some of the intestinal bacteria, for example, CA is accumulated spontaneously in energized probiotic bac teria 3, 4 , BAs in the cytoplasm of intestinal bacteria will be partially released into the intestinal lumen. Lactococcus lactis has been reported to actively release CA via a multispecific organic anion transporter 8 . Thus, well characterized probiotic strains with a strong ability for BA uptake but not BA excretion into the gastro intestinal tract could potentially be useful in this applica tion. Additionally, oral administration of BAbinding probiotics with high bile salt hydrolase activity could increase BA decon jugation in the small intestine and, therefore, facilitate greater reabsorption of decon jugated BAs from the distal ileum. Taken together, it is not clear, at this point, how pro biotics interact with BAs in vivo and whether they have a beneficial effect in depleting cyto toxic secondary BAs in the gastro intestinal tract. We will have the answers to these ques tions only after indepth mechanistic studies have been performed, particularly in vivo.
